Oppenheimer Maintains Outperform on Protara Therapeutics, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Protara Therapeutics (NASDAQ:TARA) but lowers the price target from $30 to $25.
August 12, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Protara Therapeutics but lowers the price target from $30 to $25.
The Outperform rating suggests a positive outlook, but the lowered price target indicates tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100